Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Recent studies reveal MG53 (TRIM72) enhances muscle stem cell activation and reduces inflammation, offering a novel therapeutic target for sarcopenia with promising preclinical and early clinical resu...
Recent studies link IGFBP7 from senescent cells to reduced exercise benefits in older adults, with senolytic therapies offering new avenues for enhanced fitness and healthy aging interventions. IGFBP7...
Stanford’s March 2024 study shows electric field bioprinting improves muscle fiber alignment by 40%, advancing regenerative medicine for injuries and aging, with potential clinical applications ...
A new blood test based on p-tau217 biomarker can predict Alzheimer’s symptom onset in 3-4 years with high accuracy, offering early intervention opportunities. Recent studies validate a p-tau217 ...
New research reveals Ube2g1 upregulation in hematopoietic stem cells drives immune senescence via tyrosine phosphorylation, offering insights for reversing age-related decline, based on Haematologica ...
Partial OSK reprogramming rejuvenates engram neurons in aged mice, improving memory by over 50%, with recent studies enhancing safety and biotech firms advancing towards human trials. New research sho...
A new AI system, DeepRare, demonstrates superior accuracy in diagnosing rare diseases using real-time data and self-reflective reasoning, as detailed in a 2026 Nature study, with potential to reduce d...
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
